The approval was based on data from 2 multicenter, randomized, double-blind, phase 3 trials that evaluated the efficacy and safety of Klisyri ointment in adults with AK on the face or scalp. The Food ...
Please provide your email address to receive an email when new articles are posted on . The FDA has approved the expanded use area of Klisyri to up to 100 cm 2 on the face and scalp for the treatment ...
BUFFALO, N.Y., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...
Please provide your email address to receive an email when new articles are posted on . Klisyri has received a positive opinion for the treatment of actinic keratosis from the European Medicines ...
BUFFALO, N.Y., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...
Credit: Almirall. The expanded approval was based on data from a phase 3 safety study which evaluated tirbanibulin in more than 100 adult patients with actinic keratosis. Findings showed the safety ...
BARCELONA, Spain, May 21, 2021 /PRNewswire/ -- Almirall S.A. (BME: ALM), a global biopharmaceutical company, announced today that the Committee for Medicinal Products for Human Use (CHMP) of the ...
First-in-class microtubule inhibitor indicated for the topical treatment of actinic keratosis (AK) on the face or scalp with a 5-day application course Klisyri will be manufactured by Athenex Almirall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results